English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60578
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

AuthorsBenito, Rocío; Lumbreras, Eva ; Gutiérrez, Norma Carmen; Robledo, Cristina; García, Juan L. ; Cañizo, María Consuelo del; Hernández, Jesús M.
Issue Date2012
PublisherLippincott Williams & Wilkins
CitationPharmacogenetics and Genomics 22(5): 381-388 (2012)
Abstract[Background]: Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. It is well known that CML cells are genetically unstable. However, the mechanisms by which these cells acquire genetic alterations are poorly understood. Imatinib mesylate is the standard therapy for newly diagnosed CML patients. Imatinib mesylate targets the oncogenic kinase activity of BCR-ABL. [Objective]: To study the gene expression profile of bone marrow hematopoietic cells in the same patients with CML before and 1 month after imatinib therapy. [Methods]: Samples from patients with CML were analyzed using Affymetrix GeneChip Expression Arrays. [Results]: A total of 594 differentially expressed genes, most of which (393 genes) were downregulated, as a result of imatinib therapy were observed. [Conclusion]: The blockade of oncoprotein Bcr-Abl by imatinib could cause a decrease in the expression of key DNA repair genes and substantially modify the expression profile of the bone marrow cells in the first days of therapy.
Identifiersissn: 1744-6872
e-issn: 1744-6880
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.